Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests.

Gok B, Budama-Kilinc Y, Kecel-Gunduz S

Journal of biomolecular structure & dynamics22 Jun 2023Cited by 9 (Europe PMC)

PMID37349941DOI10.1080/07391102.2023.2223681PepBankPUB-37349941

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cell-free)Activity measurement
In laboratory tests, Syn‑Ake DPPH radical scavenging activity increased with concentration.
In plain wordsIn lab tests, Syn‑Ake removed more DPPH radicals as its concentration increased.
Peptide
SYN-AKE
Outcome
IncreaseDPPH radical scavenging
Study
n: not reported in source
Outcome group
Oxidative stress · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
The results revealed the concentration-dependent increased DPPH radical scavenging activity of the peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
In addition, the antioxidant activity of Syn-Ake was investigated using diphenyl-2-picril-hydrazine (DPPH) method since it is crucial to remove free radicals that are effective in skin aging.
Report a problemFND-3734994105
02LabOther designSafety outcome
In laboratory safety tests, researchers determined a safe Syn‑Ake dose without reporting its value in the abstract.
In plain wordsIn lab tests, researchers determined a safe Syn‑Ake dose but did not report its value in the abstract.
Peptide
SYN-AKE
Outcome
Direction not reportedSafe dose determination
Study
n: not reported in source
Outcome group
Adverse events · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Finally, the safety of the Syn-Ake was investigated, and the safe dose of the peptide was determined.
Report a problemFND-3734994106

Studies that did not test the peptide alone4

In this study, SYN-AKE was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking SYN-AKE.

03Computer modelNot a test of SYN-AKE aloneIn silicoActivity measurement
Computer docking of Syn‑Ake gave MMP receptor score energies in the order MMP-13 < MMP-8 < MMP-1.
In plain wordsComputer docking predicted the reported order of Syn‑Ake binding energies across three MMP receptors.
Peptide
SYN-AKE
Outcome
Not applicablePredicted MMP docking energy order
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Skin and wound
Source sentences
Summary
The molecular docking study showed that the docking score energy of MMP receptors was in the order of MMP-13 < MMP-8 < MMP-1.
In this study, SYN-AKE was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SYN-AKE.
Report a problemFND-3734994101
04Computer modelNot a test of SYN-AKE aloneIn silicoActivity measurement
Computer docking predicted the lowest and most stable Syn‑Ake binding to SIRT1 at -9.32 kcal/mol.
In plain wordsComputer docking predicted the lowest and most stable Syn‑Ake binding to SIRT1.
Peptide
SYN-AKE
Outcome
Not applicablePredicted SIRT1 binding energy
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Skin and wound
Measurements
Binding energy
−9.32 kcal/mol
SIRT1
Source sentences
Summary
Syn-Ake peptide provided the lowest and the most stable binding to the SIRT1 receptor at -9.32 kcal/mol.
In this study, SYN-AKE was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SYN-AKE.
Report a problemFND-3734994102
05Computer modelNot a test of SYN-AKE aloneIn silicoMechanism
In molecular dynamics simulations, Syn‑Ake remained stable in the MMP-13 active site during 50 ns.
In plain wordsComputer simulations predicted stable Syn‑Ake binding in the MMP-13 active site.
Peptide
SYN-AKE
Outcome
Not applicablePredicted MMP-13 binding stability
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Skin and wound
Source sentences
Summary
The MD results showed that the Syn-Ake peptide remained stable in the active site of MMP-13 and SIRT1 receptors during 50 ns simulations.
In this study, SYN-AKE was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SYN-AKE.
Report a problemFND-3734994103
06Computer modelNot a test of SYN-AKE aloneIn silicoMechanism
In molecular dynamics simulations, Syn‑Ake remained stable in the SIRT1 active site during 50 ns.
In plain wordsComputer simulations predicted stable Syn‑Ake binding in the SIRT1 active site.
Peptide
SYN-AKE
Outcome
Not applicablePredicted SIRT1 binding stability
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Skin and wound
Source sentences
Summary
The MD results showed that the Syn-Ake peptide remained stable in the active site of MMP-13 and SIRT1 receptors during 50 ns simulations.
In this study, SYN-AKE was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SYN-AKE.
Report a problemFND-3734994104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.